GAITHERSBURG, Md., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of Josh Blacher as its Chief Financial Officer (CFO), effective immediately. This appointment comes in the wake of the untimely passing of Dane Saglio, BullFrog AI's forme ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to Commission File Number 001-41600 BULLFROG AI HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 84-4786155 (State or other j ...

GAITHERSBURG, Md., Oct. 22, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its VP Artificial Intelligence, Enrique García-Rivera, Ph.D., will present at Google’s inaugural Cancer AI Symposium on October 30, 2024, at the Boston Center for the Arts. Dr. García-Rivera’s pre ...

Core Viewpoint - BullFrog AI Holdings, Inc. has successfully closed a definitive agreement for the purchase and sale of 1,565,000 shares of common stock and common warrants, raising approximately $3.13 million in gross proceeds from the offering [1][2]. Group 1: Offering Details - The offering includes a registered direct offering and a concurrent private placement, with a combined purchase price of $2.00 per share [1]. - The common warrants have an exercise price of $2.00 per share, are initially exercisable six months from issuance, and will expire five years from the initial exercise date [1]. - The shares and warrants will be issued under an effective shelf registration statement previously filed with the SEC [3]. Group 2: Financial and Legal Aspects - The gross proceeds from the offering are expected to be approximately $3.13 million, excluding any proceeds from the exercise of the warrants and before deducting placement agent fees and other expenses [2]. - WallachBeth Capital, LLC acted as the sole placement agent for the offering, while Sheppard, Mullin, Richter & Hampton LLP served as counsel to the placement agent [2]. Group 3: Company Background - WallachBeth Capital provides a range of capital markets and investment banking services, particularly to the healthcare sector, including initial public offerings and private transactions [4].

Core Viewpoint - BullFrog AI Holdings, Inc. has successfully closed a definitive agreement for the purchase and sale of 1,565,000 shares of common stock and common warrants, raising approximately $3.13 million in gross proceeds through a registered direct offering and a concurrent private placement at a combined purchase price of $2.00 per share [1][2]. Group 1: Offering Details - The offering includes 1,565,000 shares of common stock and common warrants to purchase an equal number of shares, with an exercise price of $2.00 per share [1]. - The warrants are initially exercisable six months from the issuance date and will expire five years from that date [1]. - The gross proceeds from the offering are expected to be approximately $3.13 million, excluding any proceeds from the exercise of the warrants and before deducting placement agent fees and other expenses [2]. Group 2: Regulatory Compliance - The shares and pre-funded warrants will be issued under an effective shelf registration statement on Form S-3, previously filed with the SEC [3]. - The common warrants issued in the private placement are offered under an exemption from registration requirements and have not been registered under the Securities Act [3]. Group 3: Company Overview - BullFrog AI is a technology-enabled drug development company utilizing AI and machine learning to enhance the development of pharmaceuticals and biologics [4]. - The company employs its proprietary bfLEAP(TM) platform to analyze biological, clinical, and real-world data, aiming to streamline data analytics and reduce development costs by decreasing failure rates in therapeutics [4].

JERSEY CITY, N.J., Oct. 18, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, has entered into a definitive agreement for the purchase and sale of an aggregate of 1,565, ...

GAITHERSBURG, Md., Oct. 18, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced today it has entered into a definitive agreement for the purchase and sale of an aggregate of 1,565,000 shares of common stock (or common stock equivalents in lieu thereof) in a registered direc ...

Core Insights - The study published in Cell Reports provides mechanistic evidence for the role of β2-spectrin in obesity-related liver diseases, suggesting that targeting this protein with BF-114 can prevent disease progression [1][2] - BF-114 has shown potential in treating metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), and hepatocellular carcinoma (HCC) [1][2] - Dr. Lopa Mishra has joined BullFrog AI's Scientific Advisory Board to provide strategic insights for advancing BF-114 [1][5] Research Findings - The research indicates that β2-spectrin mediates the effects of environmental factors driving MASH progression, and BF-114 can reduce β2-spectrin levels to halt MASLD and MASH progression in animal models [2][3] - Previous studies from Dr. Mishra's laboratory support the development of BF-114 for obesity and liver diseases [3] Development Strategy - BullFrog AI plans to utilize its AI-driven platform to analyze single-cell data from animal models and human patients, which will enhance understanding of SPTBN1 silencing effects in obesity and liver disease [4] - Insights from this analysis are expected to inform the continued development of BF-114 and may uncover additional therapeutic applications [4] Leadership and Expertise - Dr. Lopa Mishra brings extensive expertise to BullFrog AI, with over 100 peer-reviewed publications and an H-Index of 66, which will be instrumental in guiding the BF-114 program [5][6] - The company emphasizes the combination of its drug development approach and promising results from BF-114 as a strong foundation for exploring its potential in treating obesity and liver diseases [6] Company Overview - BullFrog AI is a technology-enabled drug development company leveraging artificial intelligence and machine learning for pharmaceutical and biologic development [7] - The company's proprietary bfLEAP™ platform is being utilized for the development of BF-114 targeting obesity and liver diseases [7]

Revenue Recognition - The company recognized revenue of $65,000 in Q3 2023 from its first commercial service contract, with no revenue generated during the six months ended June 30, 2024[70]. Research and Development Expenses - Research and development expenses for Q2 2024 increased to $513,699, up from $273,671 in Q2 2023, reflecting a rise of $240,028[74]. - For the six months ended June 30, 2024, research and development expenses totaled $1,065,825, up from $643,604 in the same period of 2023, an increase of $422,221[75]. - Research and development expenses for the six months ended June 30, 2024, increased due to higher personnel costs from hiring additional technical staff and engaging disease experts[78]. General and Administrative Expenses - General and administrative expenses for Q2 2024 decreased to $1,168,264 from $1,263,299 in Q2 2023, a reduction of $95,035[74]. - General and administrative expenses for the six months ended June 30, 2024 were $2,581,856, compared to $2,084,011 in the same period of 2023, an increase of $497,845[75]. - General and administrative expenses for the six months ended June 30, 2024, increased primarily due to higher personnel costs and associated equity compensation costs[78]. Total Operating Expenses - Total operating expenses for Q2 2024 were $1,681,963, an increase of $144,993 compared to $1,536,970 in Q2 2023[74]. - Total operating expenses for the six months ended June 30, 2024 reached $3,647,681, up from $2,727,615 in the same period of 2023, an increase of $920,066[75]. Cash and Capital Resources - The company has a cash balance of approximately $5.6 million as of June 30, 2024, following net proceeds of approximately $5.7 million from a secondary public offering[65]. - The company anticipates requiring additional capital to continue executing its strategy, with plans to raise funds through equity sales, debt transactions, and licensing agreements[67]. - Management believes the company's capital resources are sufficient to fund planned operations for approximately 9 months from the date of this filing[84]. Financing Activities - The company completed its IPO on February 16, 2023, raising approximately $8.4 million in gross proceeds by selling 1,297,318 units at $6.50 each[82]. - In the first quarter of 2024, the company generated approximately $5.7 million in net proceeds from an underwritten secondary offering of common stock and warrants[83]. - Net cash provided by financing activities for the six months ended June 30, 2024, decreased to $6,121,507 from $8,991,410 in the same period of 2023, a decrease of $2,869,903[86]. Cash Flow - Net cash used in operating activities for the six months ended June 30, 2024, decreased to $(3,132,149) from $(3,589,511) in the same period of 2023, a change of $457,362[85]. - The net increase in cash and cash equivalents for the six months ended June 30, 2024, was $2,989,358, down from $5,401,899 in the same period of 2023, a decrease of $2,412,541[85]. Interest Income and Expense - Interest expense decreased by $59,950 for the six months ended June 30, 2024, while interest income increased by $57,662 during the same period[79]. Accumulated Deficit - The company has an accumulated deficit of approximately $13,287,000 as of June 30, 2024, funded through the sale of common stock and debt[80].

Core Insights - BullFrog AI Holdings, Inc. has made significant advancements in its collaboration with the Lieber Institute for Brain Development, focusing on identifying molecular pathways associated with bipolar disorder, which may lead to new drug targets [1][6][14] Company Developments - The research has identified specific molecular pathways in the Dentate Gyrus and Dorsolateral Prefrontal Cortex, which are critical for understanding bipolar disorder pathology [5][14] - BullFrog AI utilizes its proprietary bfLEAP™ platform and causal AI to analyze complex biological data, aiming to streamline drug development and reduce clinical trial failure rates [6][10] Research Collaboration - The Lieber Institute for Brain Development houses the world's largest brain repository for studying neuropsychiatric disorders, with over 4,300 human brains [3] - The collaboration aims to translate genetic and molecular insights into clinical advancements for bipolar disorder treatment [3][6] Findings and Implications - The analysis revealed significant enrichment in six out of 68 gene clusters related to bipolar disorder, narrowing down the gene networks involved [9] - The discoveries highlight potential dysregulation of pro-inflammatory pathways and identify novel pathways significant to bipolar disorder's pathophysiology, paving the way for targeted therapeutics [14]